The overall median survival time (MST) stratified for variables, including the BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was assessed in 41 patients with pelvic melanoma loco regional metastases who received a total of 175 treatments with melphalan hypoxic perfusion and cytoreductive excision. Here, BRAF is linked to melanoma.